Skip to main content
OpenTrials
Completed

NCT Number: NCT01507480

The ELLIPSE Study: A Phase-1 Study Evaluating the Tolerance of Bevacizumab Nasal Spray to Treat Epistaxis in Hereditary Hemorrhagic Telangiectasia

Antiangiogenic drugs, such as bevacizumab, are a new treatment strategy in Hereditary Hemorrhagic Telangiectasia (HHT). Its systemic administration in patients with HHT improves liver damage-related symptoms and epistaxis (cases reported and on-going study-ClinicalTrials.gov Identifier #NCT00843440-). To limit the systemic adverse effects of bevacizumab and to ease administration, a local administration seems suitable.

A clinical case recently showed the benefits of bevacizumab nasal spray in these patients. Its results were confirmed in a characterization study on bevacizumab transport through porcine nasal mucosa (in press).

It seems necessary to assess the tolerance and efficacy of bevacizumab nasal spray in humans for the treatment of epistaxis in HHT with a prospective phase 1 study.

The primary objective of the study is to evaluate the tolerance of increasing doses of bevacizumab administered as a nasal spray in patients with HHT-related epistaxis.

This phase-1, randomized, double-blind, placebo-controlled, monocentric study is to be carried out sequentially (dose escalation) on 5 groups of 8 patients. Each group is made up of 6 verum and 2 placebos.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Rendu Osler Disease Cardiovascular Abnormalities Cardiovascular Diseases Congenital Abnormalities Congenital, Hereditary, and Neonatal Diseases and Abnormalities Hematologic Diseases Hemic and Lymphatic Diseases Hemorrhagic Disorders Hemostatic Disorders Telangiectasia, Hereditary Hemorrhagic Telangiectasis Vascular Diseases Vascular Malformations

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥ 18 years.
  • Patients who give voluntary, informed consent and sign a consent form.
  • Patients affiliated with the French universal health care system.
  • Patients treated for HHT, that has been confirmed clinically (presence of at lease 3 Curaçao criteria) and/or by molecular biology.
  • Patients who fill out epistaxis tally sheets completely in the three months before inclusion.
  • Patients who present severe epistaxis averaging over 30 minutes in the three months before inclusion ((duration M1 + duration M2 + duration M3) / 3).
  • Patients whose number of red blood cell transfusions in the six months before inclusion is known.
  • Patients who have not undergone nasal surgery in the three months before inclusion.

Exclusion criteria

  • Pregnant women or women who could become pregnant during the study.
  • Patients not affiliated with the French universal health care system.
  • Patients who are protected adults according to the terms of the law (French public health laws).
  • Refusal to give consent.
  • Patients whose HHT diagnosis has not be confirmed clinically and/or by molecular biology.
  • Infectious episode.
  • Patients presenting unchecked hypertension at the time of inclusion (systolic BP > 150 mmHg and/or diastolic BP > 100 mmHg) with or without treatment. -Patients with hypertension can be included, once blood pressure levels have been controlled by appropriate medical treatment.
  • Participation in another therapeutic trial in the 28 days before inclusion. Patients who have already being treated with bevacizumab by intravenous infusion.
  • A known hypersensitivity to the active substance or one of its excipients.A known hypersensitivity to products containing Chinese hamster ovarian (CHO) cells or to other human or humanized recombinant antibodies.

Treatment and study plan

Bevacizumab

Drug

There are five increasing doses of bevacizumab nasal spray (25mg/mL): 10 mg, 25 mg, 50 mg, 75, mg and 100 mg. Each test dose is a single dose divided into five fractions and administered into each nostril every 30 minutes for 2 hours:

Other names: AVASTIN

Primary outcomes

  1. Tolerance

    Time frame: 3 months

    Evaluate the tolerance of increasing doses of bevacizumab administered as a nasal spray in patients with HHT-related epistaxis.

Secondary outcomes

  1. Systemic passage and pharmacokinetics

    Time frame: 3 months

    Study the systemic passage and pharmacokinetics of bevacizumab in these patients.

  2. Efficacy

    Time frame: 3 months

    Evaluate the efficacy of bevacizumab nasal spray on the appearance of epistaxis (number, frequency)

  3. Efficacy

    Time frame: 3 months

    Evaluate the efficacy of bevacizumab nasal spray on hemoglobinema and ferritin

  4. Efficacy

    Time frame: 3 months

    Evaluate the efficacy of bevacizumab nasal spray on the number of red blood cell transfusions

Sponsors and collaborators

Lead sponsor

Hospices Civils de Lyon

Other

Registry information

Official study title

The ELLIPSE Study: A Phase-1 Study Evaluating the Tolerance of Bevacizumab Nasal Spray to Treat Epistaxis in Hereditary Hemorrhagic Telangiectasia.

Acronym: ELLIPSE

Important dates

Study start
2011
Primary completion
2012
Study completion
2012
First posted
Jan 11, 2012
Registry last updated
Oct 19, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.